George L. Bakris, MD - Show Me the Data: Improving Renal Outcomes With Glucose-Lowering Therapy in the Individualized Management of T2DM

Medicine via myPod

English - January 16, 2022 12:43 - 20 minutes
Music podcasting Homepage Download Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: David R. Jones, MD - Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer

Next Episode: 2 Cups Of Water Before Each Meal Showed 44% Faster Weight Loss - Michael Greger, MD

PVI, PeerView Institute for Medical Education

Go online to PeerView.com/RBT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in cardiometabolic health discusses the role and ability of SGLT2 inhibitors to improve renal outcomes in patients with T2DM and/or CKD. Upon completion of this activity, participants should be better able to: Outline the mechanism(s) of action and clinical potential of newer options in glucose-lowering therapy that have been shown to improve renal outcomes in patients with T2DM, Evaluate the clinical efficacy and safety of newer options in glucose-lowering therapy in patients with T2DM and/or CKD, Integrate newer glucose-lowering therapies to improve the management of patients with T2DM and/or CKD based on the latest clinical evidence.

https://www.listennotes.com/e/8eb10f5ff0984ed6bbcb2d72ccbe8b0b/